HC Wainwright & Co. reiterated coverage on Dicerna Pharmaceuticals with a new price target
$DRNA
Major Pharmaceuticals
Health Care
HC Wainwright & Co. reiterated coverage of Dicerna Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $38.00 previously